← Back to Search

Palliative Care + Standard Leukemia Care for Acute Myeloid Leukemia

N/A
Waitlist Available
Led By Areej El-Jawahri, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary refractory AML
Relapsed AML
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial is looking at whether having a palliative care team work with an oncology team will improve outcomes for patients with AML.

Who is the study for?
This trial is for patients 60 years or older with newly diagnosed acute myeloid leukemia (AML), including those with a history of hematologic disorders, therapy-related AML, relapsed or primary refractory AML. It's also open to hospitalized high-risk AML patients. Those with severe psychiatric illness, other major comorbid conditions, acute promyelocytic leukemia (APML), or already in palliative care cannot participate.Check my eligibility
What is being tested?
The study is testing the effects of combining palliative care—a specialty aimed at easing symptoms and helping cope with serious illness—with standard leukemia treatment on quality of life, symptom management, mood, and end-of-life outcomes in AML patients.See study design
What are the potential side effects?
While this trial focuses on supportive care rather than direct medical treatments like chemotherapy or drugs that may have extensive side effects lists, palliative interventions can sometimes include medications that might cause drowsiness, nausea or other mild side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My AML did not respond to initial treatment.
Select...
My AML cancer has returned after treatment.
Select...
I have been recently diagnosed with AML caused by previous cancer treatment.
Select...
I am 60 or older and have been diagnosed with high-risk AML.
Select...
I have been recently diagnosed with AML following a blood disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of Patients' quality of life as measured by (FACT-Leukemia) Score at Week-2 Between Study Arms
Secondary outcome measures
Compare Patient-Report Of Discussion EOL Care Preferences Between Study Arms
Compare Patient-Reported PTSD (as per PTSD-Checklist) between study arms
Compare Rates Of Chemotherapy Administration Within 30 Days Of Death Between The Two Study Arms
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Collaborative Palliative and Oncology CareExperimental Treatment1 Intervention
Collaborative care from Palliative Care and Leukemia will be given
Group II: Standard Leukemia CareActive Control1 Intervention
Standard Leukemia care

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,198,195 Total Patients Enrolled
Duke UniversityOTHER
2,358 Previous Clinical Trials
3,419,909 Total Patients Enrolled
Areej El-Jawahri, MDPrincipal InvestigatorMassachusetts General Hospital
18 Previous Clinical Trials
4,352 Total Patients Enrolled

Media Library

Palliative Care Clinical Trial Eligibility Overview. Trial Name: NCT02975869 — N/A
Acute Myeloid Leukemia Research Study Groups: Collaborative Palliative and Oncology Care, Standard Leukemia Care
Acute Myeloid Leukemia Clinical Trial 2023: Palliative Care Highlights & Side Effects. Trial Name: NCT02975869 — N/A
Palliative Care 2023 Treatment Timeline for Medical Study. Trial Name: NCT02975869 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JAMA OncologyJournal
Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia
El-Jawahri, Areej, Thomas W. LeBlanc, Alison Kavanaugh, Jason A. Webb, Vicki A. Jackson, Toby C. Campbell, Nina O’Connor, et al.. 2021. “Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2020.6343.
clinicaltrials.govStudy
A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
El-Jawahri, Areej,M.D. 2017. "A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02975869.
All > Acute Myeloid Leukemia > Aml
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top